Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients

Digestive and Liver Disease

Volumn 40, Issue 2, 2008, Pages 108-113

  de Boer, N K H ^a   Zondervan, P E ^b   Gilissen, L P L ^c   den Hartog, G ^d   Westerveld, B D ^e   Derijks, L J J ^f   Bloemena, E ^a   Engels, L G J B ^g   van Bodegraven, A A ^a   Mulder, C J J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d RIJNSTATE HOSPITAL   (Netherlands)

^e ISALA HOSPITAL   (Netherlands)

^f MÁXIMA MEDICAL CENTER   (Netherlands)

^g Sittard Geleen Heerlen   (Netherlands)

Author keywords

6 Thioguanine; 6 Thioguaninenucleotides; Hepatotoxicity; Inflammatory bowel disease; Nodular regenerative hyperplasia; TPMT

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MESALAZINE; PREDNISONE; THIOGUANOSINE; TIOGUANINE;

ADULT; AGED; ARTHRALGIA; ARTICLE; BONE MARROW TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; ENTERITIS; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; HUMAN TISSUE; LABORATORY DIAGNOSIS; LIVER BIOPSY; LIVER TOXICITY; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MULTICENTER STUDY; MYALGIA; NODULAR HYPERPLASIA; PANCREATITIS; TREATMENT DURATION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; HUMANS; HYPERPLASIA; INFLAMMATORY BOWEL DISEASES; LIVER; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIOGUANINE; TREATMENT OUTCOME;

EID: 38049079278     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.dld.2007.10.013     Document Type: Article

References (19)

1. Al Hadithy A.F., de Boer N.K., Derijks L.J., Escher J.C., Mulder C.J., and Brouwers J.R. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 37 (2005) 282-297
2. de Jong D., Mulder C.J., and van Sorge A.A. Why measure thiopurine methyltransferase activity? Direct administration of 6-thioguanine might be the alternative for 6-mercaptopurine or azathioprine. Gut 49 (2001) 874
3. Dubinsky M.C., Hassard P.V., Seidman E.G., Kam L.Y., Abreu M.T., Targan S.R., et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 7 (2001) 181-189
4. Derijks L.J., de Jong D.J., Gilissen L.P., Engels L.G., Hooymans P.M., Jansen J.B., et al. 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. Eur J Gastroenterol Hepatol 15 (2003) 63-67
5. Dubinsky M.C., Vasiliauskas E.A., Singh H., Abreu M.T., Papadakis K.A., Tran T., et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 125 (2003) 298-303
6. Seiderer J., Zech C.J., Reinisch W., Lukas M., Diebold J., Wrba F., et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. J Hepatol 43 (2005) 303-309
7. de Boer N.K., Derijks L.J., Gilissen L.P., Hommes D.W., Engels L.G., de Boer S.Y., et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 11 (2005) 5540-5544
8. Osterman M.T., Kundu R., Lichtenstein G.R., and Lewis J.D. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 130 (2006) 1047-1053
9. de Boer N.K., Mulder C.J., and Van Bodegraven A.A. Nodular regenerative hyperplasia and thiopurines: the case for level-dependent toxicity. Liver Transpl 11 (2005) 1300-1301
10. Derijks L.J., Gilissen L.P., Engels L.G., Bos L.P., Bus P.J., Lohman J.J., et al. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy. Ther Drug Monit 26 (2004) 311-318
11. Geller S.A., Dubinsky M.C., Poordad F.F., Vasiliauskas E.A., Cohen A.H., Abreu M.T., et al. Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol 28 (2004) 1204-1211
12. Gilissen L.P., Derijks L.J., Driessen A., Bos L.P., Hooymans P.M., Stockbrügger R.W., et al. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?. Dig Liver Dis 39 (2007) 156-159
13. Vora A., Mitchell C.D., Lennard L., Eden T., Kinsey S.E., Lilleyman J., et al. Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial. Lancet 368 (2006) 1339-1348
14. Reshamwala P.A., Kleiner D.E., and Heller T. Nodular regenerative hyperplasia: not all nodules are created equal. Hepatology 44 (2006) 7-14
15. Breen D.P., Marinaki A.M., Arenas M., and Hayes P.C. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 11 (2005) 826-833
16. Wanless I.R. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 11 (1990) 787-797
17. De Bruyne R., Portmann B., Samyn M., Bansal S., Knisely A., Mieli-Vergani G., et al. Chronic liver disease related to 6-thioguanine in children with acute lymphoblastic leukaemia. J Hepatol 44 (2006) 407-410
18. Seiderer J., Zech C.J., Diebold J., Schoenberg S.O., Brand S., Tillack C., et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol 18 (2006) 553-555
19. de Boer N.K., Reinisch W., Teml A., van Bodegraven A.A., Schwab M., Lukas M., et al. 6-Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6-TG working party. Digestion 73 (2006) 25-31